Pain Therapeutics (PTIE) Sees Unusually-High Trading Volume

Shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) saw strong trading volume on Monday . 851,574 shares changed hands during trading, an increase of 187% from the previous session’s volume of 296,978 shares.The stock last traded at $1.28 and had previously closed at $1.26.

Separately, ValuEngine lowered shares of Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 25th.

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Eagle Investment Management LLC grew its position in Pain Therapeutics by 83.8% during the third quarter. First Eagle Investment Management LLC now owns 1,720,410 shares of the biopharmaceutical company’s stock valued at $1,738,000 after buying an additional 784,314 shares during the period. Renaissance Technologies LLC grew its position in Pain Therapeutics by 833.7% during the third quarter. Renaissance Technologies LLC now owns 261,083 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 233,121 shares during the period. Vanguard Group Inc grew its position in Pain Therapeutics by 20.7% during the third quarter. Vanguard Group Inc now owns 218,850 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 37,466 shares during the period. Geode Capital Management LLC grew its position in Pain Therapeutics by 75.0% during the fourth quarter. Geode Capital Management LLC now owns 66,068 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 28,314 shares during the period. Finally, BlackRock Inc. grew its position in Pain Therapeutics by 11.4% during the fourth quarter. BlackRock Inc. now owns 226,066 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 23,204 shares during the period. Institutional investors own 17.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Pain Therapeutics (PTIE) Sees Unusually-High Trading Volume” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2019/03/18/pain-therapeutics-ptie-sees-unusually-high-trading-volume.html.

Pain Therapeutics Company Profile (NASDAQ:PTIE)

Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.

Recommended Story: Sell-Side Analysts

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.